CompletedPhase 2NCT01775462
Phase 2 Study to Evaluate Safety, Pharmacokinetics, Immunogenicity and Pharmacodynamics/Efficacy of EDI200 in Male Infants With X-Linked Hypohidrotic Ectodermal Dysplasia (XLHED)
Studying Ectodermal dysplasia syndrome
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Edimer Pharmaceuticals
- Principal Investigator
- Kenneth Huttner, MD, PhDEdimer Pharmaceuticals
- Intervention
- EDI200(drug)
- Enrollment
- 6 enrolled
- Eligibility
- MALE
- Timeline
- 2013 – 2015
Study locations (7)
- University of California, San Francisco, San Francisco, California, United States
- Children's National Medical Center, Washington D.C., District of Columbia, United States
- Washington University School of Medicine, St Louis, Missouri, United States
- Hôpital Necker-Enfants Malades, Paris, France
- University Hospital Erlangen, Erlangen, Bavaria, Germany
- Azienda Ospedaliera-Polo Universitario "Luigi Sacco", Milan, Italy
- University Hospital of Wales, Cardiff, United Kingdom
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01775462 on ClinicalTrials.govOther trials for Ectodermal dysplasia syndrome
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT07468019Organization's Unique Protocol IDCairo University
- ACTIVE NOT RECRUITINGNCT07096206Characteristics and Impacts of X-linked Hypohidrotic Ectodermal Dysplasia (XLHED) in Boys: An Observational International StudyPierre Fabre Medicament
- RECRUITINGPHASE2NCT04980638Intraamniotic Administrations of ER004 to Male Subjects With X-linked Hypohidrotic Ectodermal DysplasiaEspeRare Foundation